Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced bile duct cancer or bladder cancer that has spread and standard treatments have stopped working.
- Your cancer is HER2-positive (a protein that helps cancer grow).
- You have not had treatment that targets HER2 before.
- Your heart function is good (LVEF of 50% or more).
- You are able to get out of bed and care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
This study tests a new combination of drugs for advanced bile duct cancer that has not been treated yet and shows a protein called HER2. It compares the new combination to the standard treatment to see if it works better or has fewer side effects.
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
This trial tests a new combination of drugs for people with HER2-positive bile duct or gallbladder cancer that has grown after first treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.